Cargando…
New developments in the management of hepatitis C virus infection: focus on boceprevir
Chronic hepatitis C virus infection is an important public health problem, and the standard treatment (combination of pegylated interferon-α and ribavirin) has an effectiveness rate of only 40%–50%. Novel virus-specific drugs have recently been designed, and multiple compounds are under development....
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421477/ https://www.ncbi.nlm.nih.gov/pubmed/22904616 http://dx.doi.org/10.2147/BTT.S24413 |
_version_ | 1782240967535886336 |
---|---|
author | Berenguer, Marina López-Labrador, F Xavier |
author_facet | Berenguer, Marina López-Labrador, F Xavier |
author_sort | Berenguer, Marina |
collection | PubMed |
description | Chronic hepatitis C virus infection is an important public health problem, and the standard treatment (combination of pegylated interferon-α and ribavirin) has an effectiveness rate of only 40%–50%. Novel virus-specific drugs have recently been designed, and multiple compounds are under development. The approval for the clinical use of direct-acting antivirals in 2011 (boceprevir [BOC] and telaprevir, viral NS3 protease inhibitors) has increased recovery rates by up to 70%. Therefore, a highly effective treatment has been envisioned for the first time. This paper focuses on BOC and the implementation of new BOC-based treatment regimes. |
format | Online Article Text |
id | pubmed-3421477 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-34214772012-08-19 New developments in the management of hepatitis C virus infection: focus on boceprevir Berenguer, Marina López-Labrador, F Xavier Biologics Review Chronic hepatitis C virus infection is an important public health problem, and the standard treatment (combination of pegylated interferon-α and ribavirin) has an effectiveness rate of only 40%–50%. Novel virus-specific drugs have recently been designed, and multiple compounds are under development. The approval for the clinical use of direct-acting antivirals in 2011 (boceprevir [BOC] and telaprevir, viral NS3 protease inhibitors) has increased recovery rates by up to 70%. Therefore, a highly effective treatment has been envisioned for the first time. This paper focuses on BOC and the implementation of new BOC-based treatment regimes. Dove Medical Press 2012 2012-08-03 /pmc/articles/PMC3421477/ /pubmed/22904616 http://dx.doi.org/10.2147/BTT.S24413 Text en © 2012 Berenguer and López-Labrador, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Review Berenguer, Marina López-Labrador, F Xavier New developments in the management of hepatitis C virus infection: focus on boceprevir |
title | New developments in the management of hepatitis C virus infection: focus on boceprevir |
title_full | New developments in the management of hepatitis C virus infection: focus on boceprevir |
title_fullStr | New developments in the management of hepatitis C virus infection: focus on boceprevir |
title_full_unstemmed | New developments in the management of hepatitis C virus infection: focus on boceprevir |
title_short | New developments in the management of hepatitis C virus infection: focus on boceprevir |
title_sort | new developments in the management of hepatitis c virus infection: focus on boceprevir |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421477/ https://www.ncbi.nlm.nih.gov/pubmed/22904616 http://dx.doi.org/10.2147/BTT.S24413 |
work_keys_str_mv | AT berenguermarina newdevelopmentsinthemanagementofhepatitiscvirusinfectionfocusonboceprevir AT lopezlabradorfxavier newdevelopmentsinthemanagementofhepatitiscvirusinfectionfocusonboceprevir |